A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders

Scholz, Paula; Altay, Lebriz; Fauser, Sascha

doi:10.1007/s12325-017-0559-y

“…This allows for a uniform, slow and steady application of laser energy. 6 Avoid the 3 and 9 o' clock positions as well any bleb area. The potential side effects of this procedure are post-operative pain, inflammation and infection.…”

Section: Resultsmentioning

confidence: 99%

“…It is shown to be effective in diseases like central serous retinopathy (CSR), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR) and macular edema secondary to retinal vein occlusion (RVO). 6,7 However it is only recently being used for glaucoma management. It is postulated that this laser treatment lowers intraocular pressure by increasing the existing uveoscleral outflow without actually photocoagulating the target tissue.…”

mentioning

confidence: 99%

Micropulse Laser in Glaucoma

Pandey¹

2019

Delhi Journal of Ophthalmology

0

View full text Add to dashboard Cite

A new type of diode laser-Cyclo G6 or the micropulse laser is helpful in reducing the intraocular pressure in glaucoma. It is a 810 diode laser from Iridex Corporation similar to the trans-scleral cyclophotocoagulation (TSCPC) laser but with a difference. The laser is delivered in a continuous wave fashion in TSCPC whereas in micropulse, it is delivered in short bursts with an “on time”and an “off time”. This “off time” helps the target tissue to cool down in between, thereby greatly reducing thermal damage. Thus, this could prove to be an excellent non-surgical option for glaucoma patients.

show abstract

“…[15,17,18,19,20,21,22] Final BCVA is usually given as an average value of the whole cohort of patients, which is composed of both responders and . [24] Relatively poor rate of visual improvement in CCSCR is also noted with other treatment modalities. BCVA gain in the treatment of chronic CSCR with photodynamic therapy (PDT) is similar to SMPLT, usually at the level of a few ETDRS letters or 1 Snellen line.…”

Section: Discussionmentioning

confidence: 97%

Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy

Gawęcki¹,

Jaszczuk-Maciejewska²,

Jurska-Jaśko³

et al. 2019

Preprint

1

0

View full text Add to dashboard Cite

Purpose Central serous chorioretinopathy(CSCR) is a complex ocular entity that, in its chronic form, can lead to serious visual impairment and morphological damage to the retina. The aim of the current retrospective study was to evaluate the damage present after long-standing but resolved central serous chorioretinopathy and refer it to healthy individuals. Correlations between measurable factors—for example, duration of the disease, baseline retinal morphological parameters, or patient age and/or their degree of impairment—were also assessed. Materials and methods The study group consisted of thirty-two eyes (13 female and 19 male, mean age 49.6 years SD +/- 10.5) with chronic central serous chorioretinopathy ( mean duration 18.9 months SD +/- 15.4) in which complete resolution of subretinal fluid was achieved after subthreshold micropulse laser treatment. Inclusion criterion was a lack of subretinal fluid within the whole area of the central retina scanned by the spectral domain optical coherence tomography. The group was extracted out of 51 cases of chronic CSCR that were treated with that method. They were analyzed according to final best-corrected visual acuity and retinal morphological parameters as measured by spectral optical coherence tomography with angiography option (OCTA). Results were compared with the outcomes of a control group, which consisted of 40 eyes of healthy individuals with full distance visual acuity (0.0 logMAR, 1.0 Snellen) never treated with subthreshold micropulse laser. Statistical analysis included regarding correlation between final visual acuity and final central retinal thickness and retinal and functional parameters prior to treatment. Results Final best-corrected visual acuity after chronic central serous chorioretinopathy was 0.23 logMAR (0.6 Snellen) and central retinal thickness was 39.32 µm smaller than in controls. No correlation was found between final visual acuity and retinal thickness and duration of the disease, patient age, and baseline morphological retinal parameters. OCTA scans revealed impaired choriocapillaries flow signal even following resolution of the disease. Conclusion Chronic central serous chorioretinopathy is a potentially damaging clinical entity that results in serious visual impairment, retinal thinning, and choroidal flow defects. Further research is needed to determine precisely the timepoint of this damage.

show abstract

“…[15,17,18,19,20,21,22] Final BCVA is usually given as an average value of the whole cohort of patients, which is composed of both responders and nonresponders. Koss [24] Relatively poor rate of visual improvement in CCSCR is also noted with other treatment modalities. BCVA gain in the treatment of chronic CSCR with photodynamic therapy (PDT) is similar to SMPLT, usually at the level of a few ETDRS letters or 1 Snellen line.…”

Section: Discussionmentioning

confidence: 97%

Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy

Gawęcki¹,

Jaszczuk-Maciejewska²,

Jurska-Jaśko³

et al. 2019

Preprint

0

View full text Add to dashboard Cite

Purpose Central serous chorioretinopathy(CSCR) is a complex ocular entity that, in its chronic form, can lead to serious visual impairment and morphological damage to the retina. The aim of the current retrospective study was to evaluate the damage present after long-standing but resolved central serous chorioretinopathy and refer it to healthy individuals. Correlations between measurable factors—for example, duration of the disease, baseline retinal morphological parameters, or patient age and/or their degree of impairment—were also assessed. Materials and methods The study group consisted of thirty-two eyes (13 female and 19 male, mean age 49.6 years SD +/- 10.5) with chronic central serous chorioretinopathy ( mean duration 18.9 months SD +/- 15.4) in which complete resolution of subretinal fluid was achieved after subthreshold micropulse laser treatment. Inclusion criterion was a lack of subretinal fluid within the whole area of the central retina scanned by the spectral domain optical coherence tomography. The group was extracted out of 51 cases of chronic CSCR that were treated with that method. They were analyzed according to final best-corrected visual acuity and retinal morphological parameters as measured by spectral optical coherence tomography with angiography option (OCTA). Results were compared with the outcomes of a control group, which consisted of 40 eyes of healthy individuals with full distance visual acuity (0.0 logMAR, 1.0 Snellen) never treated with subthreshold micropulse laser. Statistical analysis included regarding correlation between final visual acuity and final central retinal thickness and retinal and functional parameters prior to treatment. Results Final best-corrected visual acuity after chronic central serous chorioretinopathy was 0.23 logMAR (0.6 Snellen) and central retinal thickness was 39.32 µm smaller than in controls. No correlation was found between final visual acuity and retinal thickness and duration of the disease, patient age, and baseline morphological retinal parameters. OCTA scans revealed impaired choriocapillaries flow signal even following resolution of the disease. Conclusion Chronic central serous chorioretinopathy is a potentially damaging clinical entity that results in serious visual impairment, retinal thinning, and choroidal flow defects. Further research is needed to determine precisely the timepoint of this damage.

show abstract

A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders

Cited by 145 publications

References 76 publications

Micropulse Laser in Glaucoma

Micropulse Laser in Glaucoma

Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy

Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy

Contact Info

Product

Resources

About